Published online before print October 11, 2004, doi: 10.1161/01.CIR.0000145171.89690.B4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:2361-2367.)
© 2004 American Heart Association, Inc.
Coronary Heart Disease |
Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes
From the Institute of Cardiology (J.P.C., G.M., B.B., R.C., F.B., L.P., N.V., J.P.M., D.T.) and the Department of Biostatistics (M.L.T., J.L.G.), Pitié-Salpêtrière Hospital, Paris, France.
Correspondence to Dr G. Montalescot, Institute of Cardiology, Bureau 2–236, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 Boulevard de l’Hôpital, 75013 Paris, France. E-mail gilles.montalescot{at}psl.ap-hop-paris.fr
Received March 19, 2004; revision received June 16, 1004; accepted July 21, 2004.
Background— Oral antiplatelet agents (OAAs) can prevent further vascular events in cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical presentation of acute coronary syndromes (ACS) and clinical outcomes (death, myocardial infarction [MI]) is unclear.
Methods and Results— We studied and followed up for up to 30 days a cohort of 1358 consecutive patients admitted for a suspected ACS; of these, 930 were nonusers, 355 were prior users of OAA, and 73 had recently withdrawn OAA. Nonusers were at lower risk, more frequently presented with ST-elevation MI on admission, and more frequently had Q-wave MI at discharge than prior users (36.6% versus 17.5%, P<0.001; and 47.8% versus 28.2%, P<0.001, respectively). However, there was no difference regarding the incidence of death or MI at 30 days between nonusers and prior users (10.3% versus 12.4%, P=NS). In addition, prior users experienced more major bleeds within 30 days compared with nonusers (3.4% versus 1.4%, respectively; P=0.04). Recent withdrawers were admitted on average 11.9±0.8 days after OAA withdrawal. Interruption was primarily a physician decision for scheduled surgery (n=47 of 73). Despite a similar cardiovascular risk profile, recent withdrawers had higher 30-day rates of death or MI (21.9% versus 12.4%, P=0.04) and bleedings (13.7% versus 5.9%, P=0.03) than prior users. After multivariate analysis, OAA withdrawal was found to be an independent predictor of both mortality and bleedings at 30 days.
Conclusions— Among ACS patients, prior users represent a higher-risk population and present more frequently with non–ST-elevation ACS than nonusers. Although patients with a recent interruption of OAA resemble those chronically treated by OAA, they display worse clinical outcomes.
Key Words: acute coronary syndromes • aspirin • risk factors • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  G. Montalescot, J.-S. Hulot, and J.-P. Collet Stent thrombosis: who's guilty? Eur. Heart J., November 2, 2009; 30(22): 2685 - 2688. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Aguejouf, F. Eizayaga, V. Desplat, P. Belon, and C. Doutremepuich Prothrombotic and Hemorrhagic Effects of Aspirin Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 523 - 528. [Abstract] [PDF]
|
|
|
|
 |
|
 M Cleanthis and M. Flather The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective Clin Risk, May 1, 2009; 15(3): 106 - 108. [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Collyer, D. J. Gray, R. Sandhu, J. Berridge, and G. Lyons Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography(R) Platelet MappingTM Br. J. Anaesth., April 1, 2009; 102(4): 492 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell Antiplatelet Agents in the Perioperative Period Arch Surg, January 1, 2009; 144(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jivan, S. Southern, and S. Majumder Re: The effects of aspirin in patients undergoing carpal tunnel decompression J Hand Surg Eur Vol., December 1, 2008; 33(6): 813 - 814. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zimarino and R. De Caterina Long-term treatment strategies for atherothrombotic disease: do platelets define the course? Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I8 - I13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ho, E. D. Peterson, L. Wang, D. J. Magid, S. D. Fihn, G. C. Larsen, R. A. Jesse, and J. S. Rumsfeld Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome JAMA, February 6, 2008; 299(5): 532 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sutphin, S. Stevens, D. Kirzeder, and J. Gash Acute Thrombosis of a Mesenteric Artery Drug-Eluting Stent Following Clopidogrel Cessation Vascular and Endovascular Surgery, January 1, 2008; 41(6): 564 - 567. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Smart, S. Aragola, and P. Hutton Antiplatelet agents and anaesthesia CEACCP, October 1, 2007; 7(5): 157 - 161. [Full Text] [PDF]
|
|
|
|
|
|
P.-G. Chassot, A. Delabays, and D. R. Spahn Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction Br. J. Anaesth., September 1, 2007; 99(3): 316 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ouattara, H. Bouzguenda, Y. Le Manach, P. Leger, A. Mercadier, P. Leprince, N. Bonnet, G. Montalescot, B. Riou, and P. Coriat Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin Eur. Heart J., April 12, 2007; (2007) ehm049v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G.L. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, F. Burzotta, L. Testa, I. Sheiban, and G. Sangiorgi A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease Eur. Heart J., November 2, 2006; 27(22): 2667 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Albaladejo, E. Marret, V. Piriou, and C.-M. Samama Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br. J. Anaesth., October 1, 2006; 97(4): 580 - 582. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Collet and G. Montalescot Premature withdrawal and alternative therapies to dual oral antiplatelet therapy Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G46 - G52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Spahn, S. J. Howell, A. Delabays, and P.-G. Chassot Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. Br. J. Anaesth., June 1, 2006; 96(6): 675 - 677. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease Diabetes, March 1, 2006; 55(3): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marret, J.-P. Collet, P. Albaladejo, and G. Montalescot Thrombosis After Implantation of Drug-Eluting Stents JAMA, January 4, 2006; 295(1): 36 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sirvinskas, A. Veikutiene, P. Grybauskas, J. Cimbolaityte, A. Mongirdiene, V. Veikutis, and L. Raliene Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery Perfusion, January 1, 2006; 21(1): 61 - 66. [Abstract] [PDF]
|
|
|
|
|
|
J. T. Murphy and B. G. Fahy Thrombosis of Sirolimus-Eluting Coronary Stent in the Postanesthesia Care Unit Anesth. Analg., October 1, 2005; 101(4): 971 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ferrari, M. Benhamou, P. Cerboni, and B. Marcel Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis J. Am. Coll. Cardiol., February 1, 2005; 45(3): 456 - 459. [Abstract] [Full Text] [PDF]
|
|